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ABSTRACT
The research on the effect of melatonin on intraocular pressure (IOP) is
reviewed from the hystorical point of view of our laboratory. The original idea of
melatonin modulating intraocular pressure has been improved by using selective
compounds for MT2 and specially melatonin MT3 receptors. The selective
compound 5-methoxyamino N-acetyltryptamine (5-MCA-NAT) has been an
attractive compound due to its ability to reduce IOP about 40%, therefore being a
good candidate to the treatment of the ocular hypertension linked to glaucoma.
More compounds have been developed and tested permitting us to have a more
accurate panorama of those receptors controlling the relevant process of
intraocular pressure.
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RESUMEN
¡La melatonina me hace sentir despierto! Siete años de experiencia en
el laboratorio (2000 – 2007)
La investigación sobre el efecto de la melatonina sobre la presión intraocular
(PIO) es revisada desde la perspectiva histórica de nuestro laboratorio. La idea
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original sobre la melatonina modulando la presión intraocular ha sido mejorada
gracias al empleo de nuevos compuestos selectivos para el receptor MT2
y especialmente para el MT3. El compuesto selectivo 5-metoxiamino N-acetil-
triptamina (5-MCA-NAT) se ha convertido en un compuesto muy atractivo debido
a su capacidad de reducir la PIO hasta un 50%, convirtiéndose en un compuesto
muy interesante para el tratamiento de la hipertensión ocular asociada al glaucoma.
Se han desarrollado y ensayado más compuestos que nos han permitido tener un
panorama más preciso acerca de como estos receptores controlan el proceso
fisiológico de la presión intraocular.
Palabras clave: Melatonina, presión intraocular, receptores de melatonina,
receptor MT3.
MY HISTORICAL PERSPECTIVE
In May 1999, when I was flying back to Spain from an
Ophthalmology meeting in Florida (USA) I started to talk with a
colleague about those persons who take melatonin to avoid jet-lag in
long distance trips. Some people comment that this neurohormone
helps to recover the light/night cycles faster than when you allow
your body to do it without any help.
When I was back in the lab, I had a look to melatonin in the
internet looking for some references regarding jet-lag, and I was
surprised when I saw a graph in which the concentrations of
melatonin along 24 hours was presented. That plot showed that this
indole presented higher concentrations in the night and lower during
the day. There was something funny about this plot: it was just
opposite to one I saw in one of the most popular Ocular Physiology
books (Adler’s Physiology of the Eye) in which intraocular pressure
(IOP) was analysed along 24 hours. If you overlap both graphs you
may see that when melatonin was higher IOP was lower and vice
versa (Figure 1). Did that mean that melatonin levels modify IOP?
At that moment we were working on the effect of nucleotides on
IOP in New Zealand rabbits (1), so it would not be difficult to check
whether or not melatonin was able to change IOP. We performed
that single experiment and indeed melatonin significantly reduced
IOP, but its effect was transitory lasting no more than one hour.
This result was interesting and in some way indebted me to carry on
working on this topic, but not immediately since I was involved in
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the studies regarding nucleotides and dinucleotides as modulators of
IOP I wanted to finish.
FIGURE 1. Comparison between the concentration of melatonin and the
changes in IOP along day and night.
This delay was positive since in the months that passed from the
moment I did the experiments with melatonin to the one I started to
continue it, January 2000, a paper appeared describing some new
compounds which selectively activate the three different subtypes of
melatonin receptors, MT1, MT2 and MT3 (2) (Figure 2). Basically my
idea was to repeat that melatonin experiment and then to assay
different agonists and antagonists of the melatonin receptors in order
to pharmacologically characterise the receptor reducing IOP in
rabbits.
So, after getting a positive hypotensive effect with melatonin, the
next decision was to choose which one was going to be the following
compound to be assayed. At that moment I had bought a battery of
compounds so it was at the beginning a bit difficult to decide how
to start. I thought that assaying the newest compounds would
provide an attractive starting point if, of course, they work. The
newest substance was 5-methoxyamino N-acetyltryptamine (5-MCA-
NAT) and this was the first I assayed. When the experiments were
performed with this compound the results were amazing: IOP was
reduced almost 40 % and the duration of the effect was longer than
8 hours, just with a single dose of 100 μM 5-MCA-NAT. Compared
to melatonin, this agonist was much better than the naturally
occurring substance (Figure 3). Moreover, 5-MCA-NAT was a
selective melatonin MT3 receptor (3).
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FIGURE 2. Chemical structure of agonists and antagonists of melatonin
receptors. Melatonin is the naturally occurring agonist of melatonin receptors,
while 5-MCA-NAT and IIK7 are MT3 and MT2 selective agonists. On the other
hand antagonists are represented by luzindole (non selective), 4-PPDOT (MT2) and
Prazosin (MT3 and α1-adrenergic).
A review of the existing literature in the field brought some
interesting papers but none of them reported the existence of
melatonin MT3 receptors modulating intraocular pressure. In that
moment, melatonin and its receptors became an important part of
the research developed in the laboratory.
FIGURE 3. Changes in IOP produced by melatonin and 5-MCA-NAT. The
selective MT3 agonist presented a more profound and long lasting effect when
compared to melatonin.
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LOOKING FOR MELATONIN ANALOGUES FOR THE
TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
Working on the MT3 melatonin receptor
Most of the pharmacological approaches for the treatment of
ocular hypertension and glaucoma lie in the reduction of IOP that
is, in general, abnormally elevated in these patients. In this sense all
the approaches reduce IOP by acting on different targets (tissues)
that are relevant for the correct physiology of the aqueous humour
dynamics. These compounds, independently of their chemical na-
ture can be classified into three classes based on the mechanism
of action. Class I drugs act by reducing the production of the aqueous
humour and these include carbonic anhydrase inhibitors and
beta-blockers, among others. Class II drugs improve trabecular
meshwork outflow and these include cholinergics and epinephrines.
Class III drugs work by enhancing the uveoscleral outflow being
the most representative the prostaglandins (4).
Can we add a new group of compounds to the existing list of
pharmaceutical compounds for the treatment of glaucoma? It is a
bit soon to provide an answer to this question, nevertheless progress
has been carried out to, at least to suggest melatonins as candidates
for the treatment of this pathology (5).
Our interest in that moment was to fully characterise the effect
of melatonin and 5-MCA-NAT in New Zealand white rabbits.
Therefore, single dosage, dose-response studies and preliminary
antagonist studies permitted us to publish our first paper in the
field, paper which was cited as one of the breakthrough in the
glaucoma literature in 2001 (3). This experimental work permitted
not only to introduce melatonins as possible new drugs for the
treatment of glaucoma, but also allowed us to fill a patent which
open us some gates that permitted us to grow as a competitive
laboratory.
Both paper and patent were an excellent starting point to «make
business» with pharmaceutical companies, due to their interests in
finding new approaches to the treatment of glaucoma. Nevertheless
there were lots of things to do in order to clarify what receptors for
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melatonin are in the eye and how they can modulate IOP. So, next
was to fully characterise the changes in IOP by using all the available
melatonin compounds. Studies with agonists and antagonists
depicted a clear panorama: 5-MCA-NAT was the most potent and
effective compound reducing IOP, but not the only one, since all the
tested agonist presented effects, but no so profound to that produced
by 5-MCA-NAT. This was suggesting a major effect through MT3
receptors but never discarded the presence of the other two (MT1
and MT2). Antagonist demonstrated a predominant effect mediated
by the MT3, but again they did not discard other melatonin receptors.
This work was developed during 2001-2003 and was published finally
in 2003 (6). Another interesting result that was obtained was the fact
of blocking melatonin effect by means of cholinergic and adrenergic
receptor antagonists. These aspects revealed the close relation
between melatonin receptors and the neural components that control
both the production and the drainage of the aqueous humour. We
will come back to this point later.
Designing and synthesising analogues for the MT3 receptor
In the meantime we were carrying out the experiments previously
reported, and at the end of 2000, we started a research project with
the company INSPIRE PHARMACEUTICALS in which they
improved the pharmacological properties of these compounds by
modifying the chemical structure of the indole ring. During the
following couple of years we tested a big number of melatonin
analogues that provided interesting information on the structure-
function of the different melatonin structures regarding IOP changes
in our experimental model. Among the 50 or so tested analogues, 3
were particularly interesting since they reduced IOP to values closer
to that obtained with 5-MCA-NAT. Together with INSPIRE we filled
a US patent as well as a PCT one (worldwide). Also, INSPIRE and
other researchers were testing whether 5-MCA-NAT was useful in a
different model: The glaucomatous monkey. The group of Dr. Janet
Serle in Mount Sinai Hospital demonstrated that the topical
application of 5-MCA-NAT during two consecutive weeks signifi-
cantly reduced IOP in glaucomatous monkeys (7). These fantastic
results animated us to continue investigating with the analogues
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provided by INSPIRE. Therefore, dose-response analysis and
anatagonism experiments were performed with the best three
synthetic compounds. Dose-response analysis was OK, as expected,
but surprisingly antagonism analysis demonstrated that at least two
of the three tested compounds were acting through MT2 receptors
rather than on MT3 as expected. Another couple of questions arise:
Do we have more than the MT3 melatonin receptor controlling IOP?
Is there a MT2 as well?
MT2 receptors and IOP
It was quite evident by our previous results that a MT2 melatonin
receptor may exist and that this receptor would control IOP together
with the MT3 melatonin receptor. So, acting in a similar way as we
proceeded with 5-MCA-NAT we looked for a selective MT2 agonist,
N-butanoyl-2-(2-methoxy-6H-isoindolo [2,1-α]indol-11-yl) ethanami-
ne, abbreviated IIK7. The application of this compound to the
experimental animals reduced IOP, and this reduction was avoided
by the MT2 antagonists 4-PPDOT and DH-97.
The discovery of a receptor for melatonin that belongs to the MT2
subtype permitted us to expand our knowledge on the melatonin
physiology in the eye since this receptor has been cloned and there
are antibodies raised against it. In this sense out studies using MT2
receptor antibodies permitted to localise this receptor in the ciliary
processes, which is the place where the aqueous humour is
synthesised (Figure 4). So combining the fact that melatonin and
IIK7 reduce IOP and that the receptors are located in the ciliary
body it seems clear that MT2 receptors should reduce the production
of the aqueous humour and that reduction may be the reason for a
decrease in IOP. This makes sense since MT2 receptors are negatively
coupled to adenylate cyclase. Beta-adrenergic receptors are typically
antagonised in the pharmaceutical treatments for glaucoma, and
they are positively coupled to adenylate cyclase. Altogether the
topical application of IIK7 or melatonin finally inhibits PKA with
the concomitant fall in the IOP, which at the end is the same ultimate
effect beta-receptor antagonists produce.
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FIGURE 4. Immunohystochemical localization of MT2 melatonin receptors.
Four different views are presented in the present figure, Nomarski interferential
contrast, MT2 labelling in green, nervous system (synaptophysin)
and a combination MT2/synaptophysin (merge).
Melatonin receptors and the nervous system
In our preliminary studies about the changes in IOP by
melatonins, we were able to demonstrated that the neural
components that naturally modulate the dynamics of the aqueous
humour. Apparently both the sympathetic, the parasympathetic
components and melatonin (its receptors) are connected since the
use of cholinergic and adrenergic receptor antagonists diminished
the hypotensive effect of melatonin and 5-MCA-NAT.
Very recently we have demonstrated the importance of the
sympathetic component on the effects of melatonin and 5-MCA-NAT.
When New Zealand rabbits were treated with reserpine or 6-
hydroxydopamine (6-OHDA), the effects almost completely
disappeared (Figure 5) (8). We still do not know how these chemical
denervation abolishes the effect of indoles. Two main hypothesis can
be drawn, either MT3 melatonin receptors are located in the
noradrenergic terminals innervating the cilliary processes or
melatonin receptors need the presence of noradrenaline to be fully
functional. In the latter, noradrenaline by acting on beta receptors
may modulate melatonin receptors by phosharylation.
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FIGURE 5. Effect of the chemical denervation after treatment with 6-OH
dopamine. The application of this chemical destroys noradrenergic terminals and
this is reflected in a clear reduction in the effect of 5-MCA-NAT.
MELATONIN ON THE OCULAR SURFACE
Melatonin and its role in corneal wound healing
Corneal wound healing experiments we performed in New
Zealand white rabbits, demonstrated that after a superficial wound,
melatonin at low micromolar concentrations, significantly accelerate
the rate of healing closing the wounds faster than in the absence of
this neurohormone (9). This effect is antagonised by luzindole, this
is suggesting the presence of MT1 or MT2 melatonin receptors. We
jumped to a primary rabbit corneal epithelial cell culture in order to
perform more detailed biochemical studies. In the in vitro model the
same behaviour carried out by melatonin and luzindole was
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observed. It has been possible to demonstrate that melatonin effect
is to increase the rate of cell migration rather than mitosis. Moreover,
immunocytochemical staining of these cells demonstrate the
presence of MT2 melatonin receptors (5). So, till date both MT1 and
MT2 receptors are present in the corneal epithelium but it is not still
clear if both contribute to acelarate the rate of epithelial cell
migration or if they combine sequencially: one to facilitate cell
migration and other triggering mitosis to complete corneal re-
epithelialisation.
Melatonin and diadenosine polyphosphates two good
teammates
Very recently, it has been possible to investigate the role of
melatonin on the ocular surface and in particular on tear secretion.
Melatonin alone, topically applied to New Zealand rabbits, inhibits
tear production. This is an interesting aspect since melatonin is
elevated in the night and the rate of tear production during the nigh,
specially when sleeping is significantly reduced. So, it seems that the
general scheme fits well, when less tear is necessary melatonin is
increased therefore reducing tear production.
On the other hand the dinucleotide diadenosine tetraphoshate,
Ap4A, enhances tear production. Surprisingly, when melatonin and
Ap4A are both applied simultaneously, the amount of tear production
is enhanced 34 %, by means of a mechanism which is sensitive to
luzindole, therefore melatonin receptor dependent (10). The cross-
talk between melatonin and purinergic receptors may be the reason
for such an increase in tear production, although the detailed
mechanism is still under study.
OTHER RELEVANT ASPECTS OF MELATONIN IN THE EYE
The controversy: MT3 or QR2?
Some authors discuss on the possibility that the MT3 receptor is
not an independent melatonin receptor and it is the enzyme quinone
reductase 2. Uniquely, the MT3 has been identified as quinone
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reductase 2 (QR2), an enzyme involve in detoxification in mouse
(11). QR2 seems to have antioxidants properties although is diffi-
cult to establish a clear role in detoxification on the basis of the
currently available experiments. Furthermore, many tissues deprived
of QR2 genes lack melatonin binding sites. These data indicate that
in many cases is indeed QR2 the MT3 melatonin receptor (12).
Nevertheless, there are other cases in which it has not been possible
to match the presence of QR2 and the putative MT3 melatonin
receptor (11). Moreover unexpectedly, the binding of melatonin and
derivatives to QR2 does not inhibit the activity of the enzyme when
the natural substrate is present (menadione), although it occupies
the enzyme active site (12). The notion that arises is that binding
approaches for melatonin and derivatives on the QR2/MT3 receptor
is not enough to discard the existence of a real receptor with a clear-
cut physiological action. Moreover, in both mammals and non-
mammals there is a correlation between the pharmacological profile
of the putative MT3 receptor and the generation of IP3 and
diacylglycerol (13). Nevertheless, it is necessary investigate the
possibility of cloning a different protein from QR2 that may match
with the putative MT3 receptor to fully dissipate this controversial
point.
Cloning the MT3 receptor
This is indeed one of our main tasks at the moment. Based on the
sequences of QR2, MT1 and MT2 receptors, we are trying to hunt the
putative MT3 receptor. We have started to dive in ocular tissues and
we have cloned a DNA sequence which presents the sequence of the
MT2 melatonin receptor but which has an insert of 90 pb suggesting
it is a new specie. It is clear that it can be either a splice variant or
the MT3 receptor. The insert is not only increasing the length of the
protein encoded by the gene but also is altering the reading frame
that probably will generate a different protein from the cloned MT2.
This interesting discovery is more significant because the ocular
tissue where it has been obtained, the cornea, lacks of the QR2 gene.
We need to conclude this research since either we have the MT3
receptor or we have a MT2 receptor (splicing variant) with a different
selectivity for melatonins, in particular for 5-MCA-NAT.
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CONCLUSIONS
There is still a long way until we fully understand the relevance
of melatonin in all the ocular structures. We hope that with our
modest contribution along the recent years, we may established the
foundations for the development of new pharmacological treatments
for the ocular hypertension associated to glaucoma. A good review
on melatonin in the eye, including our findings on IOP, has been
recently published (14). The introduction of new compounds for the
treatment of glaucoma is especially relevant if we take into account
the various side effects that happen with some of the commercially
available compounds. Additionally we wish to get deeper into the
molecular mechanism underlying all these physiological effects,
including the cloning of the MT3 receptor.
ADDENDUM
Melatonin receptors overview
The actions of melatonin in tissues are carried out by several
receptors. The melatonin receptors are referred to by the letters MT.
«MT» represents melatonin receptors with a well defined functional
pharmacology in a native tissue, as well as known molecular
structure, followed by a number subscript (15).
Three mammalian melatonin receptors have been cloned so far:
MT1 (16, 17), MT2 (17), and MT3 (18). Two first are classified as uni-
que subtypes based on their molecular structure and chromosomal
localization, and the third have been affinity-purified from Syrian
hamster kidney (18).
It is particularly interesting to note that non-mammalian
melatonin receptors have been deeply investigated. We are aware
that mammalian melatonin receptors are indeed the ones reported
and classified by the IUPHAR, nonetheless many works originally
were developed in non-mammalian species providing clues for the
search of the corresponding orthologues in mammalian tissues.
Non-mammalian melatonin receptors are classified depending on
their pharmacology and kinetics. Therefore, the ML1 melatonin
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receptor is defined as a high-affinity (picomolar) site and a ML2 as
a low-affinity, (nanomolar) site (15). Originally, the nomenclature
ML1 / ML2 was the one used for both mammals and non-mammals
before the receptors were cloned. It is currently used in non-
mammalian experimental models, for that reason we consider of
interest to illustrate them.
ML1 includes the non-mammalian melatonin receptor isoforms
Mel1a, Mel1b and Mel1c. The Mel1a receptor sequence is
homologous to the mammalian MT1 receptor while the Mel1b is
equivalent to the mammalian MT2 receptor. There is another subtype
without a corresponding orthologue in mammals termed Mel1c.
Mammalian melatonin receptors types MT1 and MT2 belong to
class A rhodopsin-like GPCRs and present seven transmembrane
hydrophobic helices. MT1 and MT2 melatonin receptors are formed
from 350 and 362 aminoacids, respectively, with molecular weights
of 39-40 kDa (19). These two melatonin receptors are encoded by
genes located in different chromosomes (20). The gene for the MT1
receptor is located in position 4q35-1 (21) and the gene for the MT2
receptor in 11q21-22 (20). Both share approximately 60% homology
with each another (17). The existence of three extracellular loops
alternating with three intracellular loops to link the seven
transmembrane regions, indicate the presence of potential sites for
phosphorylation and glycosylation. The MT1 melatonin receptor has
two potential glycosylation sites in the N-terminal region (19), and
it may exist in more than one glycosylated form (17), while MT2 has
one potential glycosylation site in the N-terminal region (17, 19).
The signal transduction system associated to the activation of
MT1 or MT2 in target cells results in the inhibition of adenylate
cyclase activity (Figure 6) (22). Activation of these receptors inhibits
forskolin-induced cAMP formation with a subsequent decrease in
activated protein kinase A (23). This is the common rule in the
biochemical pathways for these two receptors, but it is not the only
mechanism in signal transduction they can trigger. Depending on
the location, organ and species, melatonin by acting on the same
receptor can activate different second messenger cascades. This fact
provides a rich variability of mechanism that are probably related to
the physiological processes that are biochemically modulated.
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Concerning the MT3 melatonin receptor, some authors have
indicated that after receptor stimulation the intracellular concen-
tration of IP3 and diacylglycerol in increased in hamster melanoma
cells and in Xenopus melanophores (13).
FIGURE 6. Schematic diagram showing the main melatonin receptors and the
second messengers system to which they are coupled.
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